
Arcellx (ACLX) Stock Forecast & Price Target
Arcellx (ACLX) Analyst Ratings
Bulls say
Arcellx Inc.'s robust development pipeline and significant advancements in CAR T therapy, exemplified by Carvykti's impressive average sales growth of 32% quarter-over-quarter over the last 12 quarters and a year-over-year revenue increase of 214%, highlight strong market demand. The expanding ability of community physicians to administer CAR T treatments, rising from 29% to 47% over the specified period, indicates growing accessibility and adoption of these therapies. Additionally, the anticipated performance of anito-cel and the company's innovative production techniques position Arcellx favorably within a competitive landscape, with projections suggesting the potential for substantial market share and revenues reaching approximately $4.7 billion by 2035.
Bears say
The analysis highlights concerns regarding Arcellx's product performance, particularly the high incidence of Grade 3-4 infections associated with its treatments, which raises potential safety issues that could hinder patient adoption. Additionally, lower projected sales estimates for anito-cel, in contrast to market consensus, reflect doubts about the overall CAR T market growth in myeloma, thereby negatively impacting the company's revenue outlook. Furthermore, barriers to CAR T adoption in community settings, combined with uncertainty in the development of future candidates, add to the unfavorable sentiment surrounding Arcellx's ability to capture its expected market share.
This aggregate rating is based on analysts' research of Arcellx and is not a guaranteed prediction by Public.com or investment advice.
Arcellx (ACLX) Analyst Forecast & Price Prediction
Start investing in Arcellx (ACLX)
Order type
Buy in
Order amount
Est. shares
0 shares